Related Experiment Videos
Drug-monoclonal antibody conjugates for cancer therapy: potentials and limitations
1Department of Cancer Research, University of Nottingham, United Kingdom.
Abstract:
The development of monoclonal antibodies against antigens associated preferentially with human tumors has reawakened interest in the use of antibodies as site-specific targeting agents for cancer therapy. There are now many reports of the construction of conjugates of drugs and toxins with antibodies which have in vitro toxic properties directed by the antibody moiety. Only recently, however, have limitations to the in vivo therapeutic application of these conjugates become appreciated. These include limited levels of antibodies accumulating in tumor deposits in patients, sometimes marked differences in the biodistribution of antibody-drug conjugates from those seen with free antibody, limited penetration of antibody and drug-antibody conjugates into tumor tissue together with heterogeneity of antigen expression within tumor, and limitation to the cytotoxicity of conjugates caused by the low drug to antibody molar ratios possible without denaturation. It is now becoming appreciated that effective development of this approach will require more than chemical conjugation of existing or even novel drugs or toxins to antibodies so that they are cytotoxic in vitro. Additional strategies will probably have to be employed, including the use of intermediate carriers to increase drug to antibody ratios in conjugates, the production of conjugates without extreme overall charge or conformation changes, techniques to increase antibody localization into tumors by, for example, regional perfusion, blood flow enhancement, or increase in antigenic expression, or the use of conjugates containing mixtures of antibodies or fragments directed against different tumor-associated antigens.
Insights
Monoclonal antibodies show promise for cancer therapy by targeting tumors. However, challenges like limited tumor accumulation and penetration hinder in vivo effectiveness, requiring new strategies for successful drug delivery.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Monoclonal antibodies (mAbs) targeting tumor-associated antigens are being explored for cancer therapy.
- Antibody-drug conjugates (ADCs) aim to deliver cytotoxic payloads specifically to cancer cells.
Purpose of the Study:
- To review the limitations of current antibody-drug conjugate strategies in vivo.
- To discuss novel approaches for enhancing the therapeutic efficacy of antibody-based cancer treatments.
Main Methods:
- Literature review of studies on antibody-drug conjugates for cancer therapy.
- Analysis of challenges in antibody biodistribution, tumor penetration, and payload delivery.
Main Results:
- ADCs face limitations including poor tumor accumulation, altered biodistribution, and insufficient penetration into tumor tissue.
- Heterogeneity of antigen expression and low drug-to-antibody ratios reduce in vitro and in vivo efficacy.
- Current chemical conjugation methods may lead to denaturation and altered antibody conformation.
Conclusions:
- Effective antibody-based cancer therapy requires strategies beyond simple chemical conjugation.
- Future directions include using intermediate carriers, optimizing conjugate properties, enhancing tumor localization, and employing multi-targeting antibodies or fragments.